KROS

14.38

0.35% -0.05

Dopo l'orario di chiusura: 14.38

Keros Therapeutics Inc (KROS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché KROS Giù? Forum Previsione

Precedente Chiudi:

$14.43

Aprire:

$14.39

Volume 24 ore:

287.73K

Relative Volume:

0.44

Capitalizzazione di mercato:

$584.05M

Reddito:

Utile/perdita netta:

$-168.05M

Rapporto P/E:

-2.8031

EPS:

-5.13

Flusso di cassa netto:

$-146.15M

1 W Prestazione:

+0.14%

1M Prestazione:

+4.89%

6M Prestazione:

+21.45%

1 anno Prestazione:

-70.99%

Intervallo 1D:

$14.19

$14.74

Intervallo di 1 settimana:

$13.64

$14.74

Portata 52W:

$9.12

$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Nome

Keros Therapeutics Inc

Settore

Healthcare (1161)

Industria

Biotechnology (651)

Telefono

617-314-6297

Indirizzo

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Dipendente

163

Cinguettio

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

KROS's Discussions on Twitter

Confronta KROS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KROS Keros Therapeutics Inc	14.38	586.08M	0	-168.05M	-146.15M	-5.13
VRTX Vertex Pharmaceuticals Inc	472.27	120.73B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	564.64	61.80B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	328.00	42.46B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	591.74	35.22B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	296.46	31.99B	3.81B	-644.79M	-669.77M	-6.24

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-10	Downgrade	BofA Securities	Buy → Neutral
2025-01-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2025-01-17	Downgrade	Wedbush	Outperform → Neutral
2024-12-16	Downgrade	Guggenheim	Buy → Neutral
2024-12-16	Reiterato	Oppenheimer	Outperform
2024-12-13	Reiterato	H.C. Wainwright	Buy
2024-12-12	Downgrade	BTIG Research	Buy → Neutral
2024-12-12	Downgrade	TD Cowen	Buy → Hold
2024-12-12	Downgrade	William Blair	Outperform → Mkt Perform
2024-11-05	Iniziato	Jefferies	Buy
2024-10-24	Iniziato	Cantor Fitzgerald	Overweight
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-09-23	Iniziato	Guggenheim	Buy
2024-06-25	Iniziato	Oppenheimer	Outperform
2024-02-21	Iniziato	William Blair	Outperform
2023-12-08	Iniziato	Wells Fargo	Overweight
2023-07-31	Iniziato	Wedbush	Outperform
2023-07-26	Iniziato	BofA Securities	Buy
2023-02-14	Iniziato	Cowen	Outperform
2022-10-18	Iniziato	Truist	Buy
2022-07-26	Iniziato	BTIG Research	Buy
2020-12-08	Reiterato	H.C. Wainwright	Buy
2020-05-04	Iniziato	H.C. Wainwright	Buy
2020-05-04	Iniziato	Jefferies	Buy
2020-05-04	Iniziato	Piper Sandler	Overweight
2020-05-04	Iniziato	SVB Leerink	Outperform

Mostra tutto

Keros Therapeutics Inc Borsa (KROS) Ultime notizie

Jul 24, 2025

How high can Keros Therapeutics Inc. stock price go in 2025Consistent high-performance stocks - jammulinksnews.com

Jul 24, 2025

Jul 23, 2025

Is Keros Therapeutics Inc. a good long term investmentExplosive wealth accumulation - jammulinksnews.com

Jul 23, 2025

What drives Keros Therapeutics Inc. stock priceHigh-profit trading signals - jammulinksnews.com

Jul 23, 2025

What analysts say about Keros Therapeutics Inc. stockFast-track wealth growth - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

Keros Therapeutics Inc. Stock Analysis and ForecastTriple-digit profit margins - jammulinksnews.com

Jul 22, 2025

Jul 19, 2025

(KROS) Trading Signals - news.stocktradersdaily.com

Jul 19, 2025

Jul 18, 2025

Should I buy Keros Therapeutics Inc. stock before earningsHigh Confidence Trade Setups - Newser

Jul 18, 2025

Jul 17, 2025

Keros Therapeutics Begins Phase 3 Trial for Elritercept - TipRanks

Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial By Investing.com - Investing.com South Africa

Jul 17, 2025

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - The Manila Times

Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial - Investing.com

Jul 17, 2025

Jul 16, 2025

Why Keros Therapeutics Inc. stock attracts strong analyst attentionLow Drawdown Trade Signals - Newser

Jul 16, 2025

How Keros Therapeutics Inc. stock performs during market volatilityFree Signals Group - Newser

Jul 16, 2025

Jul 15, 2025

What makes Keros Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser

Jul 15, 2025

Jul 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Target Price from Brokerages - MarketBeat

Jul 09, 2025

Trend Tracker for (KROS) - news.stocktradersdaily.com

Jul 09, 2025

Jul 08, 2025

Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com

Jul 08, 2025

Jul 06, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Jul 06, 2025

Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) dropped from Russell 3000 Growth Index - MarketScreener

Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value Index - MarketScreener

Jun 30, 2025

Jun 18, 2025

(KROS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025

Jun 17, 2025